Recent performance and business snapshot

Lantheus Holdings (LNTH) has drawn attention after a stretch of strong share price performance, with the stock up over the past week, month and past 3 months, while also showing a double digit 1 year total return.

The company develops diagnostic and therapeutic products used in the detection and treatment of heart disease, cancer and other conditions, reporting revenue of US$1,546.178 million and net income of US$279.031 million from its portfolio of imaging agents and related technologies.

At a share price of US$91.00, Lantheus Holdings has seen strong short term momentum, with a 1 day share price return of 5.63%, a 30 day share price return of 16.55% and a 5 year total shareholder return of 338.13%, contrasting with a 3 year total shareholder return decline of 8.43%.

If you are interested in where else capital is moving in healthcare and imaging, it may be worth scanning 35 healthcare AI stocks as a starting list of potential ideas.

With Lantheus trading at US$91.00 and sitting at a discount to analyst targets and some intrinsic value estimates, the key question for you is whether this is a genuine buying opportunity or if the market is already pricing in future growth.

Most Popular Narrative: 3.1% Undervalued

With Lantheus Holdings last closing at $91.00 against a narrative fair value of about $93.92, the most followed view sees modest upside grounded in detailed product and earnings assumptions.

The development, anticipated approval, and launch of the new high-yield PYLARIFY formulation are expected to deliver meaningful gross margin improvement and restore revenue growth for the prostate cancer imaging franchise, by expanding supply, improving geographic access, and resetting reimbursement dynamics with potential 340B price resets and three years of transitional pass-through status.

Curious what kind of revenue path, margin lift, and future earnings multiple this narrative needs to reach that fair value mark? The assumptions behind those projections lean heavily on how quickly new formulations scale, how far margins can stretch, and what profit level the stock might one day be priced on.

Result: Fair Value of $93.92 (UNDERVALUED)

However, this narrative can unravel quickly if PYLARIFY pricing pressure deepens or if recent acquisitions underdeliver on revenue and margin contributions.

Next Steps

Given the mix of optimism around growth drivers and concern about potential setbacks, it makes sense to move quickly, review the data, and test the underlying assumptions yourself, starting with 4 key rewards and 1 important warning sign.

Looking for more investment ideas?

If you stop at one stock, you risk missing better fits for your goals. Use the tools available and keep your opportunity set wide.

• Spot potential mispricings early by scanning 51 high quality undervalued stocks that combine quality fundamentals with attractive valuations.
• Prioritise resilience by checking 71 resilient stocks with low risk scores that score well on balance sheet strength and business stability.
• Get ahead of the crowd by reviewing the screener containing 23 high quality undiscovered gems that match strong fundamentals with lower market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.